ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
17 announcements
Promoter Uma Devi Chigurupati acquired 2.48 crore shares of Granules India Ltd via the open market. This transaction increases the promoter stake by 8.70%.
The company submitted its quarterly shareholding pattern disclosure as required by SEBI regulations for the period ended September 16, 2026.
Granules India allotted 2.49 crore equity shares to its promoter group upon warrant conversion, raising Rs. 1,461.50 Crore. This increases the company's total paid-up equity capital.
Granules India received Rs. 1,093 crore from the Promoter group, representing the balance 75% subscription for the conversion of 2.49 crore warrants into equity shares.
Promoter Dr. Krishna Prasad Chigurupati sold 1.72 crore equity shares of Granules India Ltd via block deal and open market, reducing aggregate promoter stake.
Granules India Q1 FY27 results show strong performance with Revenue growing 22% YoY and PAT up 60%, driven by a significant mix shift towards high-margin Complex Generics.
Granules India delivered record Q1 results, pivoting from volume-driven to a higher-margin complex generic and peptide-led platform. Profitability grew 60% YoY despite regulatory headwinds at Gagillapur, highlighting strong execution and diversification into regulated markets.
Granules India delivered a strong Q1FY27 with 22% YoY revenue growth and 60% PAT growth, driven by a portfolio shift toward high-margin Complex Generics.
Granules India Ltd reported revenue from operations of ₹1,477 Cr (+22.0% YoY) and net profit of ₹180 Cr (+59.9% YoY) for Q1 FY27.
Granules India reported Q3FY26 revenue of ₹13,879 Mn (up 22% YoY) and PAT of ₹1,502 Mn (up 28% YoY), driven by Finished Dosage growth in North America and Europe.
Granules India reported Q3FY26 revenue of ₹13,879 Mn with a 22% YoY growth. Strategy focuses on shifting from integrated to complex generics, supported by R&D and US portfolio expansion.
Granules India delivered record performance in FY26, crossing INR 5,000 Cr revenue with 65% gross margins. Management focused on complex generics and the successful integration of Senn Chemicals' peptide business.
Granules India delivered a strong Q3FY26 with 22% YoY revenue growth, despite a temporary EBITDA loss in its Acyl-S peptide CDMO business. Operating performance improved on execution and leverage.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Generics and Peptide CDMO.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift towards high-margin Complex Gx and Peptide CDMO segments.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Gx and Peptide CDMO.
Granules India Ltd reported revenue from operations of ₹1,471 Cr (+22.8% YoY) and net profit of ₹201.6 Cr (+32.6% YoY) for Q4 FY26.